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High body mass index is associated with an increased overall survival in rectal
cancer
Abstract
© Journal of Gastrointestinal Oncology. All rights reserved. Background: The impact of increased body
mass index (BMI) on clinical outcomes in locoregional rectal cancer is unknown. Methods: This is a
retrospective cohort study which included 453 consecutive rectal cancer patients undergoing definitive
treatment, with confirmed stage I, II or III rectal adenocarcinoma. The association of BMI at diagnosis
with overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS) was explored,
controlling for key covariates using multivariable analyses. BMI as defined by the World Health
Organization (WHO) is as follows: BMI <18.5-underweight; 18.5-24.9-normal; 25.0-29.9-pre-obesity;
>30-obese. Results: Overweight and obese patients had significantly better OS than underweight/normal
weight patients (5-year OS 80% for overweight, 77% for obese, and 65% for underweight/normal weight
patients, P=0.02). High BMI (>25) was significantly associated with improved OS in univariate [0.62
(0.4-0.8) P=0.007] and multivariable [0.65 (0.4-0.9) P=0.023] analyses. When stratified by stage, high BMI
was associated with improved OS in stage III patients (P=0.0009), but not stage II (P=0.21) or stage I
(0.54). High BMI was also significantly associated with improved CSS in univariate (HR 0.62, P=0.048)
and multivariable analyses (HR 0.58, P=0.03). Conclusions: In our study a BMI greater than 25 is
significantly associated with a longer OS and CSS in patients with locoregional rectal cancer. These
findings may be due to the reduced metabolic capacity for non-obese patients to deal with rectal cancer
treatment as well as the burden of disease, however further research is needed to evaluate this.
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Background: The impact of increased body mass index (BMI) on clinical outcomes in locoregional rectal
cancer is unknown.
Methods: This is a retrospective cohort study which included 453 consecutive rectal cancer patients
undergoing definitive treatment, with confirmed stage I, II or III rectal adenocarcinoma. The association of
BMI at diagnosis with overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS)
was explored, controlling for key covariates using multivariable analyses. BMI as defined by the World
Health Organization (WHO) is as follows: BMI <18.5—underweight; 18.5-24.9—normal; 25.0-29.9—preobesity; >30—obese.
Results: Overweight and obese patients had significantly better OS than underweight/normal weight
patients (5-year OS 80% for overweight, 77% for obese, and 65% for underweight/normal weight patients,
P=0.02). High BMI (>25) was significantly associated with improved OS in univariate [0.62 (0.4–0.8)
P=0.007] and multivariable [0.65 (0.4–0.9) P=0.023] analyses. When stratified by stage, high BMI was
associated with improved OS in stage III patients (P=0.0009), but not stage II (P=0.21) or stage I (0.54). High
BMI was also significantly associated with improved CSS in univariate (HR 0.62, P=0.048) and multivariable
analyses (HR 0.58, P=0.03).
Conclusions: In our study a BMI greater than 25 is significantly associated with a longer OS and CSS in
patients with locoregional rectal cancer. These findings may be due to the reduced metabolic capacity for
non-obese patients to deal with rectal cancer treatment as well as the burden of disease, however further
research is needed to evaluate this.
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Introduction
Colorectal cancer is a common and lethal malignancy,
accounting for an estimated 12.3% of all new cancers
diagnosed in 2018 and estimated 8.5% of all deaths from
cancer in 2018 in Australia (1). Obesity, as reflected by a
high body mass index (BMI), is a known risk factor for the
development of colorectal cancer (2). It has also been shown
to contribute to greater morbidity and short term postoperative complications in colorectal surgery (3). However,
the impact of BMI on longer term clinical outcomes in
locoregional rectal cancer is uncertain with conflicting
results from published studies. While some surgical series
demonstrate improved overall survival (OS) in overweight
and obese patients compared with underweight patients
(4-7), other studies have contrasting results with a decreased
survival seen in overweight/obese patients (8,9), or no
difference in OS across BMI categories (10-14).
In Australia, as well as an increasing incidence of rectal
cancer, we are also experiencing an increasing incidence of
obesity (15,16). A Queensland study (17) investigated the
impact of weight on mortality using data from 1,825 patients
diagnosed with stage I-III colorectal cancer. They
demonstrated that overweight, but not obese patients,
had an improved OS compared to those with a normal
BMI. Underweight patients had a significantly higher
mortality risk. They also found that excessive weight loss
of five kilograms or more at any period was associated with
increased all-cause and colorectal cancer-specific mortality.
We undertook this study to evaluate how BMI affects
OS, cancer specific survival (CSS) and disease-free survival
(DFS) in locoregional rectal cancer receiving curative
treatment. We present the following article in accordance
with the STROBE reporting checklist (available at http://
dx.doi.org/10.21037/jgo-20-48).
Methods
Patient cohort
Using electronic medical records and cancer registry data,
we identified all patients with histopathological confirmed
stage I, II or III rectal adenocarcinoma, undergoing
definitive treatment, that were managed in the Illawarra
Shoalhaven Local Health District (New South Wales,
Australia) between 2006-2017. Staging was based on the
8th edition of the American Joint Committee on Cancer
and College of American Joint Pathologists (AJCC) (18).
Staging was based on clinical stage for patients undergoing
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neoadjuvant therapy, or pathological stage for patients who
had surgery upfront. Patients managed with non-curative
or palliative intent were excluded. A total of 453 patients
managed with curative intent were included in the analysis,
regardless of neoadjuvant or adjuvant treatments. For each
patient the following was extracted from the medical record:
age, gender, TNM stage, presence of lymphovascular (LVI)
or perineural (PNI) invasion, histopathological grade, BMI,
length of stay (LOS), type of surgery, pretreatment CEA,
neoadjuvant/adjuvant radiotherapy and chemotherapy, and
long term outcomes including OS, CSS, and DFS. BMI
was collected at diagnosis of rectal cancer, and defined by
the World Health Organization (WHO) is as follows: BMI
<18.5—underweight, BMI 18.5–24.9—normal weight, BMI
25.0–29.9—pre-obesity, BMI >30—obese (19). BMI was
collected at the time of diagnosis.
The research was conducted in accordance with
the Declaration of Helsinki (as revised in 2013) lsinki.
This study was approved by the NSW Population &
Health Services Research Ethics Committee (LNR/15/
WGONG/61).
Statistical analysis
Our primary outcome was impact of BMI on all cause OS.
The secondary outcomes were CSS, DFS, and surgical
complications measured by LOS. Patient characteristics
were compared with ChiSq. Median values for OS, CSS,
and DFS, and corresponding 95% CI were calculated using
Kaplan-Meier methods. Unadjusted and multivariable
Cox proportional hazards regression analyses were used
to estimate the association between BMI and survival
outcomes, and to calculate corresponding hazard ratios
(HRs) and 95% confidence intervals (CIs). All variables
significant in the univariate analysis (P<0.05) were included
in the multivariable model. All statistical analyses were
performed using SAS 9.2 software (SAS Institute, Inc.,
Cary, NC, USA).
Results
Patient characteristics (n=453)
The characteristics of the included patients are summarized
in Table 1. The mean follow-up was 3.2 years. At the end of
the follow-up period, 144 (32%) patients had died, with 79
deaths (55% of deaths) due to rectal cancer. One hundred
and twenty-four (27%) patients had local recurrence or
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Table 1 Patient characteristics [n=453]
All patients

Underweight/normal weight
(BMI ≤25), N=124

Overweight /obese
(BMI >25), N=329

<65

171 [38]

50 [40]

121 [37]

65–75

151 [33]

31 [25]

120 [36]

>75

131 [29]

43 [35]

88 [27]

297 [66]

74 [60]

223 [67]

0.10

I

124 [27]

28 [23]

96 [29]

0.28

II

89 [18]

21 [17]

60 [18]

III

248 [55]

75 [60]

173 [53]

41 [10]

13 [11]

28 [9]

0.53

LVI present

85 [19]

26 [22]

59 [19]

0.41

PNI presentb

79 [18]

25 [21]

54 [17]

0.35

4 [1]

4

Normal (18.5–25)

120 [26]

120

Overweight [25–30]

198 [44]

198

Obese (>30)

131 [29]

131

Patient characteristics

P value

Age

Male sex

0.05

TNM stage

High grade
a

BMI
Underweight (<18.5)

Pre-treatment CEA
≤5

346 [76]

84 [68]

262 [80]

>5

107 [24]

40 [32]

67 [20]

Laparoscopic surgery

83 [18]

28 [23]

55 [17]

0.15

Neoadjuvant radiotherapy

172 [38]

54 [44]

118 [36]

0.10

Adjuvant chemotherapy

172 [38]

49 [39]

123 [37]

0.70

10

10

10

Median length of stay (days)
a

0.0079

b

, 27 results missing; , 16 results missing.

distal metastases from their disease. Four (1%) patients were
underweight, 120 (26%) patients had a normal BMI, 198
(44%) were overweight, and 131 (29%) were obese, similar
to reported demographics of the Australian population
(15,16). The weight groups had similar demographic and
clinicopathological characteristics, apart from pre-treatment
CEA which was less likely to be elevated in overweight and
obese patients compared to underweight/normal weight
patients (20% vs. 32%, P=0.0079). There was no significant
difference in use of laparoscopic surgery, neoadjuvant
radiotherapy or adjuvant chemotherapy, or postoperative
LOS between BMI groups (Table 1).
© Journal of Gastrointestinal Oncology. All rights reserved.

BMI and survival outcomes
Overweight and obese patients had significantly better OS
than underweight/normal weight patients (5-year OS 80%,
77%, 65% respectively, P=0.02). As there was no significant
difference in survival outcomes between overweight and
obese patients, these groups were combined for subsequent
analyses. In univariate analysis, BMI >25 was associated with
improved OS (HR 0.62; 95% CI, 0.4–0.8, P=0.007) (Table 2,
Figure 1). In multivariable analysis, after adjusting for age,
TNM stage, tumour grade, receipt of chemotherapy, and
LVI, high BMI remained significantly associated with
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Table 2 Univariate and multivariate analysis for overall survival
Patient characteristics

Univariate analysis
HR (95% CI)

Multivariate analysis
P value

HR (95% CI)

P value

1

<0.0001

Age
<65

1

<0.0001

65–75

1.57 (1.0–2.5)

1.45 (0.9–2.4)

>75

3.84 (2.5–5.8)

3.2 (2.0–5.0)

Male sex

0.77 (0.5–1.1)

0.14

TNM stage

0.033

I

1

II

1.88 (1.2–3.0)

1.85 (1.1–3.1)

III

1.29 (0.9–2.0)

1.81 (1.06–3.1)

High grade tumour

0.03

1

2.27 (1.4–3.6)

0.002

1.77 (1.1–3.0)

0.03

1.95 (1.3–2.9)

0.001

1.78 (1.3–3.1)

0.001

PNI present

1.28 (0.9–1.9)

0.24

Overweight/obese (BMI >25)

0.62 (0.4–0.8)

0.007

0.65 (0.4–0.9)

0.024

Pre-treatment CEA >5

1.30 (0.9–1.9)

0.19

Received adjuvant chemotherapy

0.57 (0.4–0.8)

0.002

0.46 (0.3–0.8)

0.002

Received radiotherapy

0.95 (0.7–1.3)

0.74

a

LVI present

b

a

b

, 27 results missing; , 16 results missing.

improved OS (HR 0.65; 95% CI, 0.4–0.9, P=0.023). When
stratified by stage, high BMI was associated with improved
OS in stage III patients (P=0.0009), but not stage II (P=0.21)
or stage I (0.54). High BMI (>25) was also significantly
associated with CSS in univariate (HR 0.62; 95% CI, 0.4–
0.99, P=0.048), and multivariable analyses (HR 0.58; 95%
CI, 0.3–0.98, P=0.03) (Figure 1).
There was no significant association of BMI and DFS
(HR 0.71; 95% CI, 0.5–1.1, P=0.08) (Figure 1). Similarly,
overweight and obese patients had no significant increased
risk of local recurrence compared to normal/underweight
patients (6% vs. 7%, P=0.64).
Discussion
The central finding of our study is that overweight and
obese patients had significantly better OS than underweight/
normal weight patients (5-year OS 80%, 77%, 65%
respectively). This association persisted after adjustment
for known confounders on multivariable analyses. Similar
results have been demonstrated by other studies in

© Journal of Gastrointestinal Oncology. All rights reserved.

colorectal cancer. Shahjehan et al. (4) found underweight
patients had poorer survival in patients with stage III and
IV disease, while Ballian et al. (6) showed improved survival
in obese rectal cancer patients. Similar results were seen by
You et al. (7), who found the 5-year disease free survival rate
was lower in the underweight patients and higher in the
obese patients with upper rectal cancer.
However, there are conflicting results in the literature,
with other studies finding no impact of BMI on CSS (12),
OS (13,14), or DFS (13). One series examining patients with
locoregional rectal cancer in Mexico showed an inferior DFS
in obese patients, although these results may be due reduced
utilization of neoadjuvant treatments in this group (8).
In our study, clinicopathological characteristics and
treatments were well matched between patient groups.
We note a significantly lower number of patients with an
elevated CEA in the overweight/obese patients despite
similar TNM stage, a result which is likely due to the larger
vascular volume and consequential haemodilution in obese
patients (20).
In the current study, BMI appeared to have a stage
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B

100

Percent survival

Percent survival

A

50
BMI ≤25

100

50
BMI ≤25

BMI >25

BMI >25

0

0
0

    5

10

0

Years

Percent survival

C

    5

10

Years

100

50
BMI ≤25
BMI >25
0
0

    5

10

Years

Figure 1 Association of BMI and (A) overall survival (B) cancer specific survival (C) disease free survival. BMI was associated with improved
OS (P=0.007) and CSS (P=0.048) but not DFS (0.08).

dependent effect, with improved OS in stage III patients
(P=0.0009), but not stage I or II. While this result is likely
to be due, in part, to study power and event numbers,
similar results have been reported by Kocarnik et al. (21),
who found that all-cause mortality was higher in overweight
patients in stage I, but lower in stage III and IV. It is
postulated that this stage dependent effect is due to the
reduced metabolic capacity of non-obese patients to cope
with the more intensive treatment regimens and increased
metabolic demands of advanced disease (22).
In addition to this concept of metabolic reserve, there
are several other key factors that may explain the improved
outcomes seen in patients with elevated BMIs. Very
large multi-institutional surgical series have also shown
improved survival in overweight and obese patients (23).
This is thought to be driven by a chronic state of low-grade
inflammation in overweight or mildly obese patients which
allow a faster response to the stress of surgery (24). More
intriguingly, hepatic steatosis due to obesity may actually
protect against the establishment of metastases, with
reduced rates of hepatic metastases seen in colorectal cancer

© Journal of Gastrointestinal Oncology. All rights reserved.

patients with hepatic steatosis (25). There appears to be a
complex interplay at the molecular level between factors
affecting obesity, the immune system and oncogenesis which
has not yet been fully established. Key areas for further
research include elucidating underlying pathophysiological
processes, studying the impact of weight change during
treatments, and identifying more robust markers of
nutrition in cancer patients.
There are several limitations in our study. This is a
retrospective study and is limited by the biases inherent
to this study design. There are likely to be additional
unmeasured confounders, such as patient comorbidities,
which have influenced the observed results. BMI is also a
crude measure of obesity and other more precise measures
may more accurately evaluate this relationship such as
mesorectal fat area or sarcopenia (26,27). BMI was also
measured at diagnosis only, and we were unable to capture
changes in BMI over time. Of particular importance,
weight loss prior to diagnosis has been shown to be a poor
prognostic factor, and is likely to have contributed to the
inferior outcomes seen in normal weight and under weight
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patients (28). Lastly, there was only a small number of
underweight patients limiting conclusions from this patient
group.
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2.
3.

Conclusions
BMI is a key consideration in outcomes for patients with
locoregional rectal cancer.
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